Navigation Links
ImaginAb, Inc. and Eurogentec S.A. Collaborate to Produce Antibody Fragments in Pichia
Date:1/31/2011

LOS ANGELES, Jan. 31, 2011 /PRNewswire/ -- ImaginAb, Inc. and Eurogentec S.A. announce a development collaboration to establish a novel system for producing engineered antibody fragments. The two companies will produce ImaginAb's optimized antibody fragments with Eurogentec's high-performance Pichia pastoris expression system. Leveraging Eurogentec's expertise in cGMP manufacturing of recombinant proteins, the collaboration will accelerate the development of ImaginAb's rich pipeline of targeted molecular imaging agents for the diagnosis and treatment management of cancer and autoimmune diseases.

"With our rapidly expanding pharma client base worldwide, ImaginAb is leveraging multiple manufacturing technologies to increase our capacity for fast, reliable protein production," said Dr. Christian Behrenbruch, CEO of ImaginAb. "Eurogentec's Pichia technology has the potential to enable us to take a fresh look at how we do extremely rapid and cost-effective translation into humans with our antibody fragment technology."

Dr. Philippe Cronet, CSO of Eurogentec commented, "We are very committed to exploring new manufacturing strategies for ImaginAb's unique products. Our technology platform is well suited to a variety of recombinant proteins including the important class of antibody fragment proteins such as those under development by ImaginAb".

About ImaginAb

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

About Eurogentec

Eurogentec is a cGMP accredited Contract Manufacturing Organization (CMO) offering process development and cGMP manufacturing services since 1994. Eurogentec manufactures recombinant proteins, plasmids, vaccines and conjugates in compliance with EU 2003/94/EC and US FDA 21CFR 210 and operates a full-service, state-of-the-art cGMP facility located in Belgium. In 2010, Eurogentec became part of Kaneka Corporation, Osaka, Japan. For more information about Eurogentec, visit www.eurogentec.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Anna Wu

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91513


'/>"/>
SOURCE ImaginAb, Inc.; Eurogentec S.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration
2. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
3. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
4. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
5. DuPont and USDA ARS to Collaborate on New E. coli Test in Beef
6. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
7. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
8. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
9. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
10. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
11. febit and TGen Collaborate to Study New DNA Capture Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):